✦ LIBER ✦

Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study

✍ Scribed by James R. Berenson; Ralph Boccia; David Siegel; Marek Bozdech; Alberto Bessudo; Edward Stadtmauer; J. Talisman Pomeroy; Ronald Steis; Marshall Flam; Jose Lutzky; Syed Jilani; Joseph Volk; Siu-Fun Wong; Robert Moss; Ravi Patel; Delina Ferretti; Kit Russell; Robert Louie; Howard S. Yeh; Regina A. Swift

Book ID: 108673941
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 573 KB
Volume: 135
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2006.06280.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 study of arsenic trioxide in pat

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

✍ Mohamad A. Hussein; Mansoor Saleh; Farhad Ravandi; James Mason; Robert M. Rifkin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

Safety and efficacy of bortezomib and me

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

✍ James R. Berenson; Hank H. Yang; Robert A. Vescio; Youram Nassir; Russell Mapes; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 164 KB

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB